Abeona Q2 Revenue Jumps 31% to $11.4M; ZEVASKYN Launch Gains Traction
ABEO sits 94% above its 52-week low of $4.
Summary
Abeona reported Q2 2026 revenue of $11.4 million, up 31% from Q1, driven by ZEVASKYN launch progress. CMS granted NTAP status effective October 1, 2026, and cash stands at $146.8 million.
Key Events · Earnings and Guidance · ABEO
-
Q2 Revenue Up 31%
Net ZEVASKYN revenue reached $11.4 million in Q2 2026, up from $8.7 million in Q1 2026, driven by five patient treatments.
-
CMS NTAP Secured
ZEVASKYN will receive New Technology Add-On Payment status from CMS effective October 1, 2026, supporting hospital adoption and Medicare patient access.
-
QTC Network Expansion
NewYork-Presbyterian/Columbia and CHOP were activated as qualified treatment centers in Q2; Cincinnati Children's was added in Q3 2026.
-
Cash Position
Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, down from $191.4 million at year-end 2025.
Analysis · ABEO · Life Sciences
Abeona's second-quarter results show accelerating commercial momentum for ZEVASKYN, its newly launched gene therapy for RDEB. Revenue grew 31% sequentially to $11.4 million, with five patients treated in the quarter and three more already in Q3. The company also secured CMS NTAP status effective October 1, 2026, which should improve hospital reimbursement and adoption. Cash remains strong at $146.8 million, providing runway through the launch phase. The net loss widened slightly to $20.2 million, but the revenue trajectory and expanding QTC network are the key takeaways for investors.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 32% of the 2040 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABEO was trading at $7.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.2M. The 52-week trading range was $4.00 to $7.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.